Junshi Expands Toripalimab to Stage II-III NSCLC
SHANGHAI, China, July 21, 2026 Junshi Biosciences has announced that the National Medical Products Administration (NMPA) has accepted a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, China, July 21, 2026 Junshi Biosciences has announced that the National Medical Products Administration (NMPA) has accepted a...
CAMBRIDGE, UK, July 22, 2026 Healx, an AI-powered clinical-stage biotechnology company, has announced that the first patient has been...
